# OnCo record ocular-toxicity (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/ocular-toxicity/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "ocular-toxicity" ;
  schema:name "Ocular toxicity (keratopathy, blurred vision)"@en ;
  schema:alternateName "ocular toxicity"@en, "ocular toxicities"@en, "eye toxicity"@en, "ocular adverse events"@en, "ocular events"@en, "keratopathy"@en, "corneal toxicity"@en, "corneal events"@en, "microcyst-like epithelial changes"@en, "MECs"@en, "blurred vision"@en, "dry eye"@en, "dry eyes"@en, "ophthalmology"@en, "eye examinations"@en, "ophthalmic examination"@en, "uveitis"@en, "serous retinopathy"@en, "retinopathy"@en, "conjunctivitis"@en ;
  schema:description "Eye problems from cancer drugs: blurred vision and corneal damage from certain ADCs (belantamab, tisotumab), retinal fluid from MEK inhibitors, and inflammation from immunotherapy. Usually reversible with dose holds, but they need regular eye examinations."@en ;
  schema:url <https://onco.cc/terms/ocular-toxicity/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Keratopathy> ;
  schema:citation <https://en.wikipedia.org/wiki/Keratopathy>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/antibody-drug-conjugate> ;
  onco:related <https://onco.cc/terms/dose-modification/>, <https://onco.cc/terms/therapeutic-index/>, <https://onco.cc/terms/tubulin-inhibitor-payloads/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/belantamab-mafodotin/> .